Share on LinkedInShare on LinkedIn

ARTICLE · 25 OCTOBER 2010

Eli Lilly Patent for Atomoxetine for use in Treating ADHD Invalid for Lack of Utility

Novopharm Limited (now known as Teva Canada Limited but hereafter referred to as Novopharm) sought a declaration under s. 60(1) of the Patent Act, R.S.C. 1985, c. P-4 that Eli Lilly and Company’s (Lilly’s) Canadian Patent No. 2,209,735 (the ‘735 Patent) was invalid and void. The ‘735 Patent claimed the use of the medicine atomoxetine for treating attention deficit hyperactivity disorder (ADHD) in three of its manifestations among all age groups (children, adolescents and adults). The ‘735 Patent

CanadaIntellectual Property

Novopharm Ltd. v. Eli Lilly and Company 2010 FC 915

Novopharm Limited (now known as Teva Canada Limited but hereafter referred to as Novopharm) sought a declaration under s. 60(1) of the Patent Act, R.S.C. 1985, c. P-4 that Eli Lilly and Company's (Lilly's) Canadian Patent No. 2,209,735 (the '735 Patent) was invalid and void. The '735 Patent claimed the use of the medicine atomoxetine for treating attention deficit hyperactivity disorder (ADHD) in three of its manifestations among all age groups (children, adolescents and adults). The '735 Patent did not claim the compound atomoxetine but only its use to treat ADHD.

In its Statement of Claim, Novopharm asserted that each of the 16 claims of the '735 Patent were invalid on the grounds of obviousness, anticipation, inutility, and incomplete disclosure concerning the selection of atomoxetine from an earlier genus patent. Lilly's Statement of Defence asserted the validity of the '735 Patent and argued that the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from